Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000936

Drug Information
NamePramlintide
SynonymsL-Tyrosinamide, L-lysyl-L-cysteinyl-L-asparaginyl-L-threonyl-L-alanyl-L-threonyl-L-cysteinyl-L-alanyl-L-threonyl-L-glutaminyl-L-arginyl-L-leucyl-L-alanyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-valyl-L-histidyl-L-seryl-L-seryl-L-asparaginyl-L-asparaginyl-L-phenylalanylglycyl-L-prolyl-L-isoleucyl-L-leucyl-L-prolyl-L-prolyl-L-threonyl-L-asparaginyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-, cyclic (2-7)-disulfide; AC0137; AC 0137; 187887-46-3; Pramlintide acetate; Pramlintide; Amylin (human) , 25-L-proline-28-L-proline-29-L-proline-; Pramlintide [USAN]; UNII-726I6TE06G; UNII-D3FM8FA78T; Triproamylin; 196078-30-5; 151126-32-8; LS-181996; LS-188084; Symlin; Pramlintide acetate hydrate; Pramlintide acetate [USAN]
CompanyAmylin Pharmaceuticals
IndicationType 1 and 2 diabetes, Obesity
[ICD9: 250, 278   ICD10: E08-E13, E66]
Phase IV completed    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C171H269N51O53S2/c1-21-81(12)130(163(268)207-110(56-78(6)7)169
(274)222-53-33-42-118(222)170(275)221-52-32-41-117(221)160(265)21
9-135(89(20)230)167(272)206-109(66-125(180)238)151(256)212-128(79
(8)9)161(266)186-68-126(239)192-111(70-223)154(259)203-107(64-123
(178)236)152(257)218-134(88(19)229)166(271)195-98(136(181)241)57-
92-43-45-94(231)46-44-92)214-159(264)116-40-31-51-220(116)127(240
)69-187-141(246)101(58-90-34-24-22-25-35-90)199-148(253)105(62-12
1(176)234)201-149(254)106(63-122(177)235)202-155(260)112(71-224)2
09-156(261)113(72-225)208-146(251)103(60-93-67-184-75-188-93)205-
162(267)129(80(10)11)213-150(255)100(55-77(4)5)198-145(250)102(59
-91-36-26-23-27-37-91)200-147(252)104(61-120(175)233)196-137(242)
82(13)189-144(249)99(54-76(2)3)197-142(247)96(39-30-50-185-171(18
2)183)193-143(248)97(47-48-119(174)232)194-165(270)132(86(17)227)
215-138(243)83(14)190-157(262)114(73-276)211-168(273)133(87(18)22
8)216-139(244)84(15)191-164(269)131(85(16)226)217-153(258)108(65-
124(179)237)204-158(263)115(74-277)210-140(245)95(173)38-28-29-49
-172/h22-27,34-37,43-46,67,75-89,95-118,128-135,223-231,276-277H,
21,28-33,38-42,47-66,68-74,172-173H2,1-20H3,(H2,174,232)(H2,175,2
33)(H2,176,234)(H2,177,235)(H2,178,236)(H2,179,237)(H2,180,238)(H
2,181,241)(H,184,188)(H,186,266)(H,187,246)(H,189,249)(H,190,262)
(H,191,269)(H,192,239)(H,193,248)(H,194,270)(H,195,271)(H,196,242
)(H,197,247)(H,198,250)(H,199,253)(H,200,252)(H,201,254)(H,202,26
0)(H,203,259)(H,204,263)(H,205,267)(H,206,272)(H,207,268)(H,208,2
51)(H,209,261)(H,210,245)(H,211,273)(H,212,256)(H,213,255)(H,214,
264)(H,215,243)(H,216,244)(H,217,258)(H,218,257)(H,219,265)(H4,18
2,183,185)/t81-,82-,83-,84-,85+,86+,87+,88+,89+,95-,96-,97-,98-,9
9-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,11
2-,113-,114-,115-,116-,117-,118-,128-,129-,130-,131-,132-,133-,13
4-,135-/m0/s1
InChIKeyNRKVKVQDUCJPIZ-MKAGXXMWSA-N
Canonical SMILESCCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC
(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=
O)NC(CC3=CC=C(C=C3)O)C(=O)N)NC(=O)C4CCCN4C(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=
O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC6=CN=CN6)NC
(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(=O)N)NC(=O)C
(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=
O)C(C)NC(=O)C(CS)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)
NC(=O)C(CS)NC(=O)C(CCCCN)N    
Isomeric SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=
O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=
O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]
(CC3=CC=C(C=C3)O)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=
C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H]
(CO)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)
[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)
NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=
O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@
H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N
CAS NumberCAS 151126-32-8
FormulaC171H269N51O53S2
PubChem Compound IDCID 16132446.
PubChem Substance IDSID 3819781.
SuperDrug ATC IDA10BX05
A10BX05
ClinicalTrials.govNCT00502138;
TargetGlucagon-like peptide 1 receptorAgonist[1]
Ref 1Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543